Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 346

1.

Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study.

Hatleberg CI, Ryom L, Kamara D, De Wit S, Law M, Phillips A, Reiss P, D'Arminio Monforte A, Mocroft A, Pradier C, Kirk O, Kovari H, Bonnet F, El-Sadr W, Lundgren JD, Sabin C; D:A:D Study Group.

EClinicalMedicine. 2019 Aug 11;13:91-100. doi: 10.1016/j.eclinm.2019.07.008. eCollection 2019 Aug.

2.

Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study.

Ryom L, Dilling Lundgren J, Reiss P, Kirk O, Law M, Ross M, Morlat P, Andreas Fux C, Fontas E, De Wit S, D'Arminio Monforte A, El-Sadr W, Phillips A, Ingrid Hatleberg C, Sabin C, Mocroft A; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.

J Infect Dis. 2019 Oct 8;220(10):1629-1634. doi: 10.1093/infdis/jiz369.

PMID:
31504669
3.

Serious clinical events in HIV-positive persons with chronic kidney disease (CKD).

Ryom L, Lundgren JD, Law M, Kirk O, El-Sadr W, Bonnet F, Weber R, Fontas E, Monforte AD, Phillips A, Reiss P, de Wit S, Hatleberg CI, Sabin C, Mocroft A; D:A:D study group.

AIDS. 2019 Aug 2. doi: 10.1097/QAD.0000000000002331. [Epub ahead of print]

PMID:
31385862
4.

Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART).

Hayes RJ, Donnell D, Floyd S, Mandla N, Bwalya J, Sabapathy K, Yang B, Phiri M, Schaap A, Eshleman SH, Piwowar-Manning E, Kosloff B, James A, Skalland T, Wilson E, Emel L, Macleod D, Dunbar R, Simwinga M, Makola N, Bond V, Hoddinott G, Moore A, Griffith S, Deshmane Sista N, Vermund SH, El-Sadr W, Burns DN, Hargreaves JR, Hauck K, Fraser C, Shanaube K, Bock P, Beyers N, Ayles H, Fidler S; HPTN 071 (PopART) Study Team.

N Engl J Med. 2019 Jul 18;381(3):207-218. doi: 10.1056/NEJMoa1814556.

5.

Optimizing HIV prevention and treatment outcomes for persons with substance use in Central Asia: what will it take?

Deryabina AP, El-Sadr WM.

Curr Opin HIV AIDS. 2019 Sep;14(5):374-380. doi: 10.1097/COH.0000000000000565.

6.

Brief Report: Durability of the Effect of Financial Incentives on HIV Viral Load Suppression and Continuity in Care: HPTN 065 Study.

El-Sadr WM, Beauchamp G, Hall HI, Torian LV, Zingman BS, Lum G, Elion RA, Buchacz K, Burns D, Zerbe A, Gamble T, Donnell DJ; HPTN 065 Study.

J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):300-303. doi: 10.1097/QAI.0000000000001927.

7.

AIDS in America - Back in the Headlines at Long Last.

El-Sadr WM, Mayer KH, Rabkin M, Hodder SL.

N Engl J Med. 2019 May 23;380(21):1985-1987. doi: 10.1056/NEJMp1904113. Epub 2019 May 1. No abstract available.

PMID:
31042822
8.

The HIV response and global health.

Glass RI, El-Sadr W, Goosby E, Kupfer LE.

Lancet. 2019 Apr 27;393(10182):1696. doi: 10.1016/S0140-6736(19)30353-8. No abstract available.

PMID:
31034374
9.

Host country responses to non-communicable diseases amongst Syrian refugees: a review.

Akik C, Ghattas H, Mesmar S, Rabkin M, El-Sadr WM, Fouad FM.

Confl Health. 2019 Mar 22;13:8. doi: 10.1186/s13031-019-0192-2. eCollection 2019. Review.

10.

Strengthening the Quality and Quantity of the Nursing and Midwifery Workforce: Report on Eight Years of the NEPI Project.

Michaels-Strasser S, Smith J, Khanyola J, Sutton R, Price T, El Sadr WM.

Ann Glob Health. 2018 Apr 30;84(1):31-35. doi: 10.29024/aogh.6.

11.

The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study.

Adamson B, El-Sadr W, Dimitrov D, Gamble T, Beauchamp G, Carlson JJ, Garrison L Jr, Donnell D.

Value Health. 2019 Feb;22(2):194-202. doi: 10.1016/j.jval.2018.09.001. Epub 2018 Nov 2.

PMID:
30711064
12.

Underreported injection drug use and its potential contribution to reported increase in sexual transmission of HIV in Kazakhstan and Kyrgyzstan.

Deryabina AP, Patnaik P, El-Sadr WM.

Harm Reduct J. 2019 Jan 5;16(1):1. doi: 10.1186/s12954-018-0274-2.

13.

Where are the positives? HIV testing in sub-Saharan Africa in the era of test and treat.

De Cock KM, Barker JL, Baggaley R, El Sadr WM.

AIDS. 2019 Feb 1;33(2):349-352. doi: 10.1097/QAD.0000000000002096. No abstract available.

PMID:
30557162
14.

Persons living with HIV with advanced HIV disease: need for novel care models.

Teasdale CA, Yuengling K, Preko P, Syowai M, Ndagije F, Rabkin M, Abrams EJ, El-Sadr WM.

J Int AIDS Soc. 2018 Dec;21(12):e25210. doi: 10.1002/jia2.25210.

15.

Correction to: China's health assistance to Africa: opportunism or altruism?

Lin S, Gao L, Reyes M, Cheng F, Kaufman J, El-Sadr WM.

Global Health. 2018 Oct 1;14(1):95. doi: 10.1186/s12992-018-0411-4.

16.

Response Rates of Medical Providers to Internet Surveys Regarding Their Adoption of Preexposure Prophylaxis for HIV: Methodological Implications.

Silverman TB, Schrimshaw EW, Franks J, Hirsch-Moverman Y, Ortega H, El-Sadr WM, Colson PW.

J Int Assoc Provid AIDS Care. 2018 Jan-Dec;17:2325958218798373. doi: 10.1177/2325958218798373.

17.

Cost-effectiveness of a combination strategy to enhance the HIV care continuum in Swaziland: Link4Health.

Stevens ER, Li L, Nucifora KA, Zhou Q, McNairy ML, Gachuhi A, Lamb MR, Nuwagaba-Biribonwoha H, Sahabo R, Okello V, El-Sadr WM, Braithwaite RS.

PLoS One. 2018 Sep 17;13(9):e0204245. doi: 10.1371/journal.pone.0204245. eCollection 2018.

18.

HIV Care Continuum in Adults and Children: Cost-Effectiveness Considerations.

Harripersaud K, McNairy M, Ahmed S, Abrams EJ, Thirumurthy H, El-Sadr WM.

In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 4.

19.

Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Hatleberg CI, Ryom L, d'Arminio Monforte A, Fontas E, Reiss P, Kirk O, El-Sadr W, Phillips A, de Wit S, Dabis F, Weber R, Law M, Lundgren JD, Sabin C; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.

HIV Med. 2018 Oct;19(9):605-618. doi: 10.1111/hiv.12639. Epub 2018 Jul 18.

20.

Tuberculosis preventive treatment preferences among care givers of children in Lesotho: a pilot study.

Hirsch-Moverman Y, Mantell JE, Lebelo L, Wynn C, Hesseling AC, Howard AA, Nachman S, Frederix K, Maama LB, El-Sadr WM.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):858-862. doi: 10.5588/ijtld.17.0809.

PMID:
29991393
21.

Building on the HIV chronic care platform to address noncommunicable diseases in sub-Saharan Africa: a research agenda.

Vorkoper S, Kupfer LE, Anand N, Patel P, Beecroft B, Tierney WM, Ferris R, El-Sadr WM; HIV/NCD Project.

AIDS. 2018 Jul 1;32 Suppl 1:S107-S113. doi: 10.1097/QAD.0000000000001898.

22.

Integrating cardiovascular disease risk factor screening into HIV services in Swaziland: lessons from an implementation science study.

Rabkin M, Palma A, McNairy ML, Gachuhi AB, Simelane S, Nuwagaba-Biribonwoha H, Bongomin P, Okello VJ, Bitchong RA, El-Sadr WM.

AIDS. 2018 Jul 1;32 Suppl 1:S43-S46. doi: 10.1097/QAD.0000000000001889.

23.

Building on the HIV platform: tackling the challenge of noncommunicable diseases among persons living with HIV.

El-Sadr WM, Goosby E.

AIDS. 2018 Jul 1;32 Suppl 1:S1-S3. doi: 10.1097/QAD.0000000000001886.

PMID:
29952785
24.

Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.

Shepherd L, Ryom L, Law M, Petoumenos K, Hatleberg CI, d'Arminio Monforte A, Sabin C, Bower M, Bonnet F, Reiss P, de Wit S, Pradier C, Weber R, El-Sadr W, Lundgren J, Mocroft A; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.

Clin Infect Dis. 2019 Feb 1;68(4):650-657. doi: 10.1093/cid/ciy508.

PMID:
29912335
25.

Associations between serum albumin and serious non-AIDS events among people living with HIV.

Ronit A, Hatleberg CI, Ryom L, Bonnet F, El-Sadr W, Reiss P, Weber R, Pradier C, De Wit S, Law M, d'Arminio Monforte A, Lundgren J, Mocroft A, Phillips AN, Sabin CA; D:A:D Study Group.

AIDS. 2018 Aug 24;32(13):1837-1848. doi: 10.1097/QAD.0000000000001900.

26.

Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D: A: D Cohort Analysis.

Achhra AC, Sabin C, Ryom L, Hatleberg C, Antonella d ľAminio M, de Wit S, Phillips A, Pradier C, Weber R, Reiss P, El-Sadr W, Bonnet F, Mocroft A, Lundgren J, Law MG; D:A:D Study Group.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):579-588. doi: 10.1097/QAI.0000000000001722.

PMID:
29771788
27.

HIV Population Surveys - Bringing Precision to the Global Response.

Justman JE, Mugurungi O, El-Sadr WM.

N Engl J Med. 2018 May 17;378(20):1859-1861. doi: 10.1056/NEJMp1801934. No abstract available.

28.

Achieving the fourth 90: healthy aging for people living with HIV.

Harris TG, Rabkin M, El-Sadr WM.

AIDS. 2018 Jul 31;32(12):1563-1569. doi: 10.1097/QAD.0000000000001870. No abstract available.

29.

Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.

Ryom L, Lundgren JD, El-Sadr W, Reiss P, Kirk O, Law M, Phillips A, Weber R, Fontas E, d' Arminio Monforte A, De Wit S, Dabis F, Hatleberg CI, Sabin C, Mocroft A; D:A:D study group.

Lancet HIV. 2018 Jun;5(6):e291-e300. doi: 10.1016/S2352-3018(18)30043-2. Epub 2018 May 3.

PMID:
29731407
30.

A time-motion study of cardiovascular disease risk factor screening integrated into HIV clinic visits in Swaziland.

Palma AM, Rabkin M, Simelane S, Gachuhi AB, McNairy ML, Nuwagaba-Biribonwoha H, Bongomin P, Okello VN, Bitchong RA, El-Sadr WM.

J Int AIDS Soc. 2018 Mar;21(3):e25099. doi: 10.1002/jia2.25099.

31.

Improving pathology and laboratory medicine in low-income and middle-income countries: roadmap to solutions.

Sayed S, Cherniak W, Lawler M, Tan SY, El Sadr W, Wolf N, Silkensen S, Brand N, Looi LM, Pai SA, Wilson ML, Milner D, Flanigan J, Fleming KA.

Lancet. 2018 May 12;391(10133):1939-1952. doi: 10.1016/S0140-6736(18)30459-8. Epub 2018 Mar 15. Review.

PMID:
29550027
32.

A pragmatic approach to monitor and evaluate implementation and impact of differentiated ART delivery for global and national stakeholders.

Ehrenkranz PD, Calleja JM, El-Sadr W, Fakoya AO, Ford N, Grimsrud A, Harris KL, Jed SL, Low-Beer D, Patel SV, Rabkin M, Reidy WJ, Reinisch A, Siberry GK, Tally LA, Zulu I, Zaidi I.

J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25080.

33.

Multiple strategies to identify HIV-positive black men who have sex with men and transgender women in New York City: a cross-sectional analysis of recruitment results.

Franks J, Mannheimer SB, Hirsch-Moverman Y, Hayes-Larson E, Colson PW, Ortega H, El-Sadr WM.

J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25091.

34.

The Global HIV Epidemic: What Will It Take to Get to the Finish Line?

Katz IT, Ehrenkranz P, El-Sadr W.

JAMA. 2018 Mar 20;319(11):1094-1095. doi: 10.1001/jama.2018.2093. No abstract available.

PMID:
29509836
35.

Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group.

J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25083.

36.

It's all in the timing: Acceptability of a financial incentive intervention for linkage to HIV care in the HPTN 065 (TLC-Plus) study.

Shelus V, Taylor J, Greene E, Stanton J, Pack A, Tolley EE, Branson BM, El-Sadr WM, Pollydore J, Gamble T.

PLoS One. 2018 Feb 2;13(2):e0191638. doi: 10.1371/journal.pone.0191638. eCollection 2018.

37.

Patient-level and program-level monitoring and evaluation of differentiated service delivery for HIV: a pragmatic and parsimonious approach is needed.

Reidy WJ, Rabkin M, Syowai M, Schaaf A, El-Sadr WM.

AIDS. 2018 Jan 28;32(3):399-401. doi: 10.1097/QAD.0000000000001723. No abstract available.

38.

Factors Associated with Use of Short-Term Pre-Exposure Prophylaxis for HIV Among Female Partners of Migrant Miners in Mozambique.

Falcao J, Zerbe A, Lahuerta M, Baggaley R, Ahoua L, DiMattei P, Morales F, Ramiro I, El-Sadr WM.

AIDS Patient Care STDS. 2017 Dec;31(12):528-534. doi: 10.1089/apc.2017.0179.

PMID:
29211515
39.

Expanding Hospital Human Immunodeficiency Virus Testing in the Bronx, New York and Washington, District of Columbia: Results From the HPTN 065 Study.

Branson BM, Chavez PR, Hanscom B, Greene E, McKinstry L, Buchacz K, Beauchamp G, Gamble T, Zingman BS, Telzak E, Naab T, Fitzpatrick L, El-Sadr WM; HIV Prevention Trials Network (HPTN) 065 Study Team.

Clin Infect Dis. 2018 May 2;66(10):1581-1587. doi: 10.1093/cid/cix1053.

40.

Selecting a viral load threshold for routine monitoring in resource-limited settings: optimizing individual health and population impact.

Ellman TM, Alemayehu B, Abrams EJ, Arpadi S, Howard AA, El-Sadr WM.

J Int AIDS Soc. 2017 Nov;20 Suppl 7. doi: 10.1002/jia2.25007. No abstract available.

41.

The PREVENT study to evaluate the effectiveness and acceptability of a community-based intervention to prevent childhood tuberculosis in Lesotho: study protocol for a cluster randomized controlled trial.

Hirsch-Moverman Y, Howard AA, Frederix K, Lebelo L, Hesseling A, Nachman S, Mantell JE, Lekhela T, Maama LB, El-Sadr WM.

Trials. 2017 Nov 21;18(1):552. doi: 10.1186/s13063-017-2184-0.

42.

Realizing the potential of routine viral load testing in sub-Saharan Africa.

El-Sadr WM, Rabkin M, Nkengasong J, Birx DL.

J Int AIDS Soc. 2017 Nov;20 Suppl 7. doi: 10.1002/jia2.25010. No abstract available.

43.

"Testing, Testing": Multiple HIV-Positive Tests among Patients Initiating Antiretroviral Therapy in Ethiopia.

Kulkarni S, Tymejczyk O, Gadisa T, Lahuerta M, Remien RH, Melaku Z, El-Sadr W, Elul B, Nash D, Hoffman S.

J Int Assoc Provid AIDS Care. 2017 Nov/Dec;16(6):546-554. doi: 10.1177/2325957417737840. Epub 2017 Nov 9.

PMID:
29117777
44.

Effectiveness of a combination strategy for linkage and retention in adult HIV care in Swaziland: The Link4Health cluster randomized trial.

McNairy ML, Lamb MR, Gachuhi AB, Nuwagaba-Biribonwoha H, Burke S, Mazibuko S, Okello V, Ehrenkranz P, Sahabo R, El-Sadr WM.

PLoS Med. 2017 Nov 7;14(11):e1002420. doi: 10.1371/journal.pmed.1002420. eCollection 2017 Nov.

45.

Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study.

Boyd MA, Mocroft A, Ryom L, Monforte AD, Sabin C, El-Sadr WM, Hatleberg CI, De Wit S, Weber R, Fontas E, Phillips A, Bonnet F, Reiss P, Lundgren J, Law M.

PLoS Med. 2017 Nov 7;14(11):e1002424. doi: 10.1371/journal.pmed.1002424. eCollection 2017 Nov.

46.

Reaching global HIV/AIDS goals: What got us here, won't get us there.

El-Sadr WM, Harripersaud K, Rabkin M.

PLoS Med. 2017 Nov 7;14(11):e1002421. doi: 10.1371/journal.pmed.1002421. eCollection 2017 Nov.

47.

Abacavir use and risk of recurrent myocardial infarction.

Sabin CA, Ryom L, d'Arminio Monforte A, Hatleberg CI, Pradier C, El-Sadr W, Kirk O, Weber R, Phillips AN, Mocroft A, Bonnet F, Law M, de Wit S, Reiss P, Lundgren JD; D:A:D Study Group.

AIDS. 2018 Jan 2;32(1):79-88. doi: 10.1097/QAD.0000000000001666.

PMID:
29028664
48.

A Randomized-Controlled Trial of Computer-based Prevention Counseling for HIV-Positive Persons (HPTN 065).

McKinstry LA, Zerbe A, Hanscom B, Farrior J, Kurth AE, Stanton J, Li M, Elion R, Leider J, Branson B, El-Sadr WM.

J AIDS Clin Res. 2017 Jul;8(7). pii: 714. doi: 10.4172/2155-6113.1000714. Epub 2017 Jul 26.

49.

Advanced Human Immunodeficiency Virus Disease at Diagnosis in Mozambique and Swaziland.

Kujawski SA, Lamb MR, Lahuerta M, McNairy ML, Ahoua L, Abacassamo F, Nuwagaba-Biribonwoha H, Gachuhi A, El-Sadr WM, Elul B.

Open Forum Infect Dis. 2017 Jul 23;4(3):ofx156. doi: 10.1093/ofid/ofx156. eCollection 2017 Summer. Erratum in: Open Forum Infect Dis. 2018 Jan 30;5(1):ofx191.

50.

Understanding low sensitivity of community-based HIV rapid testing: experiences from the HPTN 071 (PopART) trial in Zambia and South Africa.

Bock P, Phiri C, Piwowar-Manning E, Kosloff B, Mandla N, Young A, James A, Schaap A, Scheepers M, Donnell D, Griffith S, El-Sadr W, Shanaube K, Beyers N, Hayes R, Fidler S, Ayles H; HPTN 071 (PopART) Study Team.

J Int AIDS Soc. 2017 Aug 29;20(Suppl 6):21780. doi: 10.7448/IAS.20.7.21780.

Supplemental Content

Loading ...
Support Center